Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy

Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Joaquim Bellmunt(Dana-Farber Cancer Institute), Guru Sonpavde(AdventHealth Orlando), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Dean F. Bajorin(Memorial Sloan Kettering Cancer Center), William Oh(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Thomas E. Hutson(Texas Tech University), Noah M. Hahn(Johns Hopkins University), Robert Dreicer(University of Virginia), Cora N. Sternberg(Cornell University)
Journal of Clinical Oncology
May 10, 2011
10.1200/jco.2011.34.8433
Cited by 686

Related Papers

Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k